Lexaria Bioscience Updates on GLP-1 Oral Market Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy LEXX?
Lexaria Bioscience provides an update of additional recent developments in the fast-moving glucagon-like peptide-1 oral market. The company said, " The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy, was approved by the US Food and Drug Administration on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybelsus was the only FDA approved GLP-1 drug available in pill form, but it was approved for diabetes control and only used secondarily for weight loss. Within less than the first two months of its launch, Novo Nordisk had disclosed that over 600,000 prescriptions for the Wegovy pill had been written, and will report on its first-quarter sales including the Wegovy pill in May. Both the Wegovy injectable and the Wegovy pill contain the same active drug: semaglutide, with which Lexaria has conducted extensive testing to determine compatibility with Lexaria's DehydraTECH technology. According to Global Data Healthcare, 51% of the growth in Wegovy revenue between 2026 and 2031 is expected to come from the pill format, with injectable semaglutide expected to reach peak revenue in 2030, when Novo Nordisk's Wegovy semaglutide franchise is expected to reach $15.9 billion in annual revenue. This will be quite an achievement since 2025 semaglutide revenue derived from Wegovy was 100% in the injectable category, whereas 2031 revenue from Wegovy products is expected to be 17% from pills. As Lexaria's press release of March 24 noted, TD Cowen raised their previous 2030 sales forecast of the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis is forecasting sales of $180 billion by 2035, while UBS Investment Bank expects 2029 GLP-1 sales to reach $126 billion. It is not possible to know in advance, what overall portion of the GLP-1 market will be captured by the oral pill format vs. the traditional injectable format; but, if the Wegovy based semaglutide revenue projections are any indication, it could certainly be 17% or higher within a few short years of product launch. In fact, according to a Novo Nordisk executive, oral GLP-1 drugs may account for as much as 33% of the broader GLP-1 market by that time. Based on the various GLP-1 revenue forecasts ranging from $101 billion to $180 billion, this could imply an oral pill sector ranging in size from $17 billion to $60 billion by the mid 2030's."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEXX
Wall Street analysts forecast LEXX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.674
Low
1.50
Averages
1.50
High
1.50
Current: 0.674
Low
1.50
Averages
1.50
High
1.50
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
HC Wainwright Raises Agios Price Target to $62
- Price Target Increase: HC Wainwright & Co. raised the price target for Agios Pharmaceuticals from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating, indicating strong confidence in the company's future growth prospects.
- Market Performance: Agios Pharmaceuticals shares closed at $29.17 on Wednesday, suggesting that despite the price target increase, the current stock price remains undervalued compared to the new target, reflecting market skepticism about its potential.
- Competitive Analysis: In contrast to Agios's price target increase, Lexaria Bioscience's target was cut to $1.5, highlighting significant differences in market outlooks for various biotech companies.
- Capital One Outlook: BTIG raised the price target for Capital One Financial from $264 to $308, with analyst Vincent Caintic maintaining a Buy rating, reflecting optimism about the financial institution's future performance.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results
- Significant Study Results: Lexaria achieved the primary endpoint in the GLP-1-H24-4 study, with all four DehydraTECH test arms demonstrating good safety, as DHT-semaglutide showed a 47.9% reduction in adverse events compared to Rybelsus, laying a solid foundation for future clinical applications.
- Adverse Event Reduction: The DHT-semaglutide formulation exhibited a 54.9% reduction in gastrointestinal adverse events, highlighting its safety advantages, which may attract more pharmaceutical companies to consider its product development.
- Funding Support: Lexaria secured approximately $7.5 million through two transactions since August 31, providing a financial runway for prospective new development opportunities in 2026, thereby enhancing its viability in a competitive market.
- Future Plans: Lexaria intends to pursue follow-on clinical testing to explore the potential of a DehydraTECH + SNAC + semaglutide composition, aiming to further validate its application prospects in diabetes treatment.
See More
Lexaria Bioscience Completes GLP-1 Study, Achieves Nearly 50% Reduction in Side Effects
- Significant Study Results: Lexaria's completed GLP-1-H24-4 study in Australia demonstrated that DHT-semaglutide achieved approximately 47.9% fewer adverse events compared to Novo Nordisk's Rybelsus, indicating its potential in safety and tolerability.
- Reduction in Side Effects: The gastrointestinal adverse events from DHT-semaglutide were reduced by 54.9%, which not only enhances patient experience but also may bolster Lexaria's competitive position in the GLP-1 market.
- Future Research Plans: Lexaria intends to further develop DHT-semaglutide and is considering incorporating salcaprozate sodium in future clinical tests to potentially enhance efficacy and compare it against Rybelsus.
- Data Sharing Agreement: Lexaria will provide the complete dataset from GLP-1-H24-4 to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026, to ensure adequate time for data review.
See More
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
HC Wainwright Raises Agios Price Target to $62
- Price Target Increase: HC Wainwright & Co. raised the price target for Agios Pharmaceuticals from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating, indicating strong confidence in the company's future growth prospects.
- Market Performance: Agios Pharmaceuticals shares closed at $29.17 on Wednesday, suggesting that despite the price target increase, the current stock price remains undervalued compared to the new target, reflecting market skepticism about its potential.
- Competitive Analysis: In contrast to Agios's price target increase, Lexaria Bioscience's target was cut to $1.5, highlighting significant differences in market outlooks for various biotech companies.
- Capital One Outlook: BTIG raised the price target for Capital One Financial from $264 to $308, with analyst Vincent Caintic maintaining a Buy rating, reflecting optimism about the financial institution's future performance.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results
- Significant Study Results: Lexaria achieved the primary endpoint in the GLP-1-H24-4 study, with all four DehydraTECH test arms demonstrating good safety, as DHT-semaglutide showed a 47.9% reduction in adverse events compared to Rybelsus, laying a solid foundation for future clinical applications.
- Adverse Event Reduction: The DHT-semaglutide formulation exhibited a 54.9% reduction in gastrointestinal adverse events, highlighting its safety advantages, which may attract more pharmaceutical companies to consider its product development.
- Funding Support: Lexaria secured approximately $7.5 million through two transactions since August 31, providing a financial runway for prospective new development opportunities in 2026, thereby enhancing its viability in a competitive market.
- Future Plans: Lexaria intends to pursue follow-on clinical testing to explore the potential of a DehydraTECH + SNAC + semaglutide composition, aiming to further validate its application prospects in diabetes treatment.
See More
Lexaria Bioscience Completes GLP-1 Study, Achieves Nearly 50% Reduction in Side Effects
- Significant Study Results: Lexaria's completed GLP-1-H24-4 study in Australia demonstrated that DHT-semaglutide achieved approximately 47.9% fewer adverse events compared to Novo Nordisk's Rybelsus, indicating its potential in safety and tolerability.
- Reduction in Side Effects: The gastrointestinal adverse events from DHT-semaglutide were reduced by 54.9%, which not only enhances patient experience but also may bolster Lexaria's competitive position in the GLP-1 market.
- Future Research Plans: Lexaria intends to further develop DHT-semaglutide and is considering incorporating salcaprozate sodium in future clinical tests to potentially enhance efficacy and compare it against Rybelsus.
- Data Sharing Agreement: Lexaria will provide the complete dataset from GLP-1-H24-4 to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026, to ensure adequate time for data review.
See More
